A Phase 2 interventional study of ADX-102 Ophthalmic Solution (0.5%) and ADX-102 Ophthalmic Solution (0.1%) in Dry Eye Syndromes, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-16.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 1st registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 6
First in 2017; this study’s year is marked. 1 started in 2017.
This study's enrollment of 51 is below the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 158 across the 11 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc., this one is the 13th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 2, and was the 1st registered.
Aldeyra Therapeutics, Inc.’s Dry Eye Syndromes studies by the year they started, since 2017.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Aldeyra Therapeutics, Inc.’s 13 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ADX-102 Ophthalmic Solution (0.5%)
Drug: ADX-102 Ophthalmic Solution (0.1%)
Drug: ADX-102 Ophthalmic Lipid Solution (0.5%)
ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale.
Change from baseline of ADX-102 on ocular discomfort in subjects with dry eye disease using the Ora Calibra® Ocular Discomfort Scale (0 = least, 4 = most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
Time frame: Efficacy assessment period (Day 1 through Day 29), Day 29 reported.
| Milestone | ADX-102 Ophthalmic Solution (0.5%) | ADX-102 Ophthalmic Solution (0.1%) | ADX-102 Ophthalmic Lipid Solution (0.5%) |
|---|---|---|---|
| Started | 17 | 17 | 17 |
| Completed | 12 | 16 | 11 |
| Not completed | 5 | 1 | 6 |
Change from baseline of ADX-102 on ocular discomfort in subjects with dry eye disease using the Ora Calibra® Ocular Discomfort Scale (0 = least, 4 = most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
| units on a scale | ADX-102 Ophthalmic Solution (0.1%) | ADX-102 Ophthalmic Solution (0.5%) | ADX-102 Ophthalmic Lipid Solution (0.5%) |
|---|---|---|---|
| Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale. | -0.81 ± 0.98 | -0.75 ± 0.75 | -0.82 ± 1.33 |
Collected over The period of time over which adverse events were collected for each subject in the clinical trial was approximately four weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADX-102 Ophthalmic Solution (0.5%) | 0/17 (0%) | 0/17 (0%) | 17/17 (100%) |
| ADX-102 Ophthalmic Solution (0.1%) | 0/17 (0%) | 0/17 (0%) | 8/17 (47.1%) |
| ADX-102 Ophthalmic Lipid Solution (0.5%) | 0/17 (0%) | 0/17 (0%) | 17/17 (100%) |
| Event | ADX-102 Ophthalmic Solution (0.5%) | ADX-102 Ophthalmic Solution (0.1%) | ADX-102 Ophthalmic Lipid Solution (0.5%) |
|---|---|---|---|
| Instillation site irritationGeneral disorders | 17/17 | 8/17 | 16/17 |
| Instillation site discomfortGeneral disorders | 0/17 | 0/17 | 1/17 |
| Vision blurredEye disorders | 1/17 | 0/17 | 1/17 |
| Eyelid margin crustingEye disorders | 0/17 | 0/17 | 1/17 |
| Ocular discomfortEye disorders | 0/17 | 0/17 | 1/17 |
| DiarrheaGastrointestinal disorders | 1/17 | 0/17 | 0/17 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/17 | 1/17 | 0/17 |
| Age, Categorical(Participants) | ADX-102 Ophthalmic Solution (0.5%) | ADX-102 Ophthalmic Solution (0.1%) | ADX-102 Ophthalmic Lipid Solution (0.5%) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 7 | 4 | 18 |
| >=65 years | 10 | 10 | 13 | 33 |
| Sex: Female, Male(Participants) | ADX-102 Ophthalmic Solution (0.5%) | ADX-102 Ophthalmic Solution (0.1%) | ADX-102 Ophthalmic Lipid Solution (0.5%) | Total |
|---|---|---|---|---|
| Female | 14 | 9 | 11 | 34 |
| Male | 3 | 8 | 6 | 17 |
| Ethnicity (NIH/OMB)(Participants) | ADX-102 Ophthalmic Solution (0.5%) | ADX-102 Ophthalmic Solution (0.1%) | ADX-102 Ophthalmic Lipid Solution (0.5%) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 2 |
| Not Hispanic or Latino | 15 | 17 | 17 | 49 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | ADX-102 Ophthalmic Solution (0.5%) | ADX-102 Ophthalmic Solution (0.1%) | ADX-102 Ophthalmic Lipid Solution (0.5%) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 16 | 15 | 17 | 48 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Iris Color (Right Eye)(participants) | ADX-102 Ophthalmic Solution (0.5%) | ADX-102 Ophthalmic Solution (0.1%) | ADX-102 Ophthalmic Lipid Solution (0.5%) | Total |
|---|---|---|---|---|
| Black | 0 | 0 | 0 | 0 |
| Blue | 7 | 2 | 5 | 14 |
| Brown | 6 | 13 | 6 | 25 |
| Hazel | 3 | 1 | 4 | 8 |
| Green | 1 | 1 | 2 | 4 |
| Gray | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 |
| Iris Color (Left Eye)(participants) | ADX-102 Ophthalmic Solution (0.5%) | ADX-102 Ophthalmic Solution (0.1%) | ADX-102 Ophthalmic Lipid Solution (0.5%) | Total |
|---|---|---|---|---|
| Black | 0 | 0 | 0 | 0 |
| Blue | 7 | 2 | 5 | 14 |
| Brown | 6 | 13 | 6 | 25 |
| Hazel | 3 | 1 | 4 | 8 |
| Green | 1 | 1 | 2 | 4 |
| Gray | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Jul 2017, 1 month.
Results were first posted in Jan 2025, 7 years 6 months after primary completion. A results delay was requested in Jun 2018.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 1 month is below that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Reproxalap